Immunomedics (IMMU) Income Statement

Click line-items for a historical chart and %

Revenues:
Product sales	597.51K
Research and development	129.19K
Total revenues	741.81K
Costs and Expenses:
Costs of goods sold	255.11K
Research and development	14.53M
Sales and marketing	215.86K
General and administrative	691.58K
Total costs and expenses	15.69M
Operating loss	-14.95M
Interest and other income	85.21K
Foreign currency transaction gain	2.46K
Loss before income tax expense
Income tax (expense)	0
Net (loss)	-16.23M
Less net (loss) attributable to noncontrolling interest	-31.05K
Net (loss) attributable to Immunomedics, Inc. stockholders	-16.2M
(Loss) per common share attributable to Immunomedics, Inc. stockholders, (basic and diluted)	-0.17
Weighted average shares used to calculate loss per common share, (basic and diluted)
Comprehensive (loss):
Net (loss)
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments
Unrealized gain on securities available for sale - net	-32.61K
Other comprehensive (loss) income
Comprehensive (loss)	-16.19M

Entities mentioned with IMMU